Literature DB >> 25700114

Immunostaining in lung cancer for the clinician. Commonly used markers for differentiating primary and metastatic pulmonary tumors.

John M Carney1, Alyssa M Kraynie, Victor L Roggli.   

Abstract

Immunohistochemical stains have become invaluable for the diagnosis of pulmonary malignancies (both primary and metastatic), particularly given the small size of transbronchial and endobronchial biopsies and the increasing need to conserve tissue for molecular studies. There are many panels of immunostains currently available to help differentiate between common types of pulmonary malignancies. It is the purpose of this review to summarize some of the most commonly used immunostains for the distinction of primary pulmonary malignancies from one another in areas with histological overlap and for distinguishing primary pulmonary malignancies from other cancers with which they may be confused. These include differentiating between poorly differentiated adenocarcinoma and poorly differentiated squamous cell carcinoma, small cell/large cell neuroendocrine carcinoma and basaloid carcinoma, and primary and metastatic adenocarcinoma involving the lung. In addition, we address the distinction between mesothelioma and pulmonary adenocarcinoma. Pitfalls in the use of these markers are also addressed. Although not aiming to be comprehensive, this review aims to guide and influence common practice by furthering the clinician's knowledge on using immunohistochemical stains for characterization of pulmonary neoplasms. This summary of frequently used immunohistochemical stains can provide usefulness by allowing accurate characterization of pulmonary tumors, thereby allowing for conservation of tissue for additional molecular testing.

Entities:  

Keywords:  differential diagnosis; immunohistochemistry; pulmonary malignancies

Mesh:

Substances:

Year:  2015        PMID: 25700114     DOI: 10.1513/AnnalsATS.201501-004FR

Source DB:  PubMed          Journal:  Ann Am Thorac Soc        ISSN: 2325-6621


  3 in total

1.  An Unusual Presentation of Duodenal Metastasis of a Previously Undiagnosed Primary Lung Adenocarcinoma.

Authors:  Sai Karthik Kommineni; Syed M Sadiq; Tharun Bandarupalli; Deidre M Pierce
Journal:  Cureus       Date:  2022-05-13

2.  Survival impact of locoregional metachronous malignancy in survival of lung cancer patients who received curative treatment.

Authors:  Chi-Tsung Wen; Jui-Ying Fu; Ching-Feng Wu; Ming-Ju Hsieh; Yun-Hen Liu; Yi-Cheng Wu; Ying-Huang Tsai; Ching-Yang Wu
Journal:  J Thorac Dis       Date:  2016-06       Impact factor: 2.895

3.  CytoMatrix for a reliable and simple characterization of lung cancer stem cells from malignant pleural effusions.

Authors:  Sara Bruschini; Simona di Martino; Maria Elena Pisanu; Luigi Fattore; Claudia De Vitis; Valentina Laquintana; Simonetta Buglioni; Eugenio Tabbì; Andrea Cerri; Paolo Visca; Gabriele Alessandrini; Francesco Facciolo; Christian Napoli; Marcella Trombetta; Antonio Santoro; Anna Crescenzi; Gennaro Ciliberto; Rita Mancini
Journal:  J Cell Physiol       Date:  2019-08-09       Impact factor: 6.384

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.